Collegium Pharmaceutical (NASDAQ:COLL) Shares Gap Up to $31.50

Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report)'s stock price gapped up before the market opened on Monday . The stock had previously closed at $31.50, but opened at $33.18. Collegium Pharmaceutical shares last traded at $32.59, with a volume of 101,541 shares changing hands.

Analyst Upgrades and Downgrades

COLL has been the topic of a number of research analyst reports. Piper Sandler downgraded shares of Collegium Pharmaceutical from an "overweight" rating to a "neutral" rating and set a $39.00 price objective on the stock. in a research report on Friday. Needham & Company LLC lowered Collegium Pharmaceutical from a "buy" rating to a "hold" rating in a research report on Friday. StockNews.com lowered Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Wednesday, May 1st. Finally, Truist Financial increased their price objective on Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a "buy" rating in a report on Monday, February 26th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $39.00.

Collegium Pharmaceutical Price Performance

The stock has a 50 day moving average of $37.42 and a two-hundred day moving average of $32.50. The company has a debt-to-equity ratio of 1.98, a quick ratio of 1.14 and a current ratio of 1.21. The firm has a market capitalization of $1.05 billion, a P/E ratio of 13.40 and a beta of 1.06.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings data on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share for the quarter, topping analysts' consensus estimates of $1.20 by $0.25. Collegium Pharmaceutical had a net margin of 16.46% and a return on equity of 104.98%. The business had revenue of $149.75 million during the quarter, compared to analysts' expectations of $147.66 million. Sell-side analysts predict that Collegium Pharmaceutical, Inc. will post 5.63 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several hedge funds have recently modified their holdings of COLL. Pacer Advisors Inc. lifted its position in shares of Collegium Pharmaceutical by 68.4% in the 4th quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company's stock worth $66,938,000 after acquiring an additional 883,380 shares during the period. SummerHaven Investment Management LLC boosted its stake in Collegium Pharmaceutical by 1.1% during the fourth quarter. SummerHaven Investment Management LLC now owns 34,034 shares of the specialty pharmaceutical company's stock worth $1,048,000 after buying an additional 368 shares in the last quarter. Natixis Advisors L.P. increased its holdings in Collegium Pharmaceutical by 152.9% in the 3rd quarter. Natixis Advisors L.P. now owns 54,359 shares of the specialty pharmaceutical company's stock valued at $1,215,000 after buying an additional 32,865 shares during the period. Loomis Sayles & Co. L P raised its stake in shares of Collegium Pharmaceutical by 32.7% in the 3rd quarter. Loomis Sayles & Co. L P now owns 273,628 shares of the specialty pharmaceutical company's stock valued at $6,116,000 after buying an additional 67,439 shares in the last quarter. Finally, New York State Common Retirement Fund raised its stake in shares of Collegium Pharmaceutical by 1,475.5% in the 4th quarter. New York State Common Retirement Fund now owns 201,112 shares of the specialty pharmaceutical company's stock valued at $6,190,000 after buying an additional 188,347 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.